Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rongqing Baohua suppository powder for carotid atherosclerosis
ChiCTR2100049499Phase 2Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Aug 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of Rongqing Baohua suppository powder in hyperlipidemia and carotid atheroma (CAS) (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoints: Blood lipids and Carotid atherosclerotic plaque. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
Rongqing Baohua suppository powder
03
Conditions
hyperlipidemiacarotid atheroma (CAS)
Beyond the preview
Go deeper on ChiCTR2100049499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049499.